

Table 17: Summary of Demographic and Baseline Characteristics

Country Variable Category/Statistic	Placebo (N=86)	Xanomeline Low Dose (N=96)	Xanomeline High Dose (N=72)	Total (N=254)
CANADA				
Pooled Age Group 1, n (%)				
18-64	14 (16%)	8 (8%)	11 (15%)	33 (13%)
>64	72 (84%)	88 (92%)	61 (85%)	221 (87%)
Gender, n (%)				
Male	33 (38%)	41 (43%)	37 (51%)	111 (44%)
Female	53 (62%)	55 (57%)	35 (49%)	143 (56%)
Age (years)				
n	86	96	72	254
Mean	75.2	76.0	73.8	75.1
Median	76.0	78.0	75.5	77.0
SD	8.59	8.11	7.94	8.25
Min	52	51	56	51
Max	89	88	88	89

-
- 1.) Baseline is defined as the last non-missing value prior to the first dose.
 - 2.) Treatment duration is calculated as: (last dose date - first dose date) + 28 days.
 - 3.) Age is collected in years.

Table 17: Summary of Demographic and Baseline Characteristics

Country Variable Category/Statistic	Placebo (N=86)	Xanomeline Low Dose (N=96)	Xanomeline High Dose (N=72)	Total (N=254)
CANADA				
Race, n (%)				
AMERICAN INDIAN OR ALASKA NATIVE	0 (0%)	0 (0%)	1 (1%)	1 (0%)
BLACK OR AFRICAN AMERICAN	8 (9%)	6 (6%)	9 (12%)	23 (9%)
WHITE	78 (91%)	90 (94%)	62 (86%)	230 (91%)
Ethnicity, n (%)				
HISPANIC OR LATINO	3 (3%)	6 (6%)	3 (4%)	12 (5%)
NOT HISPANIC OR LATINO	83 (97%)	90 (94%)	69 (96%)	242 (95%)
Total Treatment Duration (Days)				
n	85	95	72	252
Mean	149.5	86.8	112.2	115.2
Median	182.0	63.0	96.5	132.0
SD	60.35	70.47	65.52	70.71
Min	7	1	15	1
Max	210	212	200	212

-
- 1.) Baseline is defined as the last non-missing value prior to the first dose.
 - 2.) Treatment duration is calculated as: (last dose date - first dose date) + 28 days.
 - 3.) Age is collected in years.

Table 17: Summary of Demographic and Baseline Characteristics

Country Variable Category/Statistic	Placebo (N=86)	Xanomeline Low Dose (N=96)	Xanomeline High Dose (N=72)	Total (N=254)
USA				
Pooled Age Group 1, n (%)				
18-64	14 (16%)	8 (8%)	11 (15%)	33 (13%)
>64	72 (84%)	88 (92%)	61 (85%)	221 (87%)
Gender, n (%)				
Male	33 (38%)	41 (43%)	37 (51%)	111 (44%)
Female	53 (62%)	55 (57%)	35 (49%)	143 (56%)
Age (years)				
n	86	96	72	254
Mean	75.2	76.0	73.8	75.1
Median	76.0	78.0	75.5	77.0
SD	8.59	8.11	7.94	8.25
Min	52	51	56	51
Max	89	88	88	89

-
- 1.) Baseline is defined as the last non-missing value prior to the first dose.
 - 2.) Treatment duration is calculated as: (last dose date - first dose date) + 28 days.
 - 3.) Age is collected in years.

Table 17: Summary of Demographic and Baseline Characteristics

Country Variable Category/Statistic	Placebo (N=86)	Xanomeline Low Dose (N=96)	Xanomeline High Dose (N=72)	Total (N=254)
USA				
Race, n (%)				
AMERICAN INDIAN OR ALASKA NATIVE	0 (0%)	0 (0%)	1 (1%)	1 (0%)
BLACK OR AFRICAN AMERICAN	8 (9%)	6 (6%)	9 (12%)	23 (9%)
WHITE	78 (91%)	90 (94%)	62 (86%)	230 (91%)
Ethnicity, n (%)				
HISPANIC OR LATINO	3 (3%)	6 (6%)	3 (4%)	12 (5%)
NOT HISPANIC OR LATINO	83 (97%)	90 (94%)	69 (96%)	242 (95%)
Total Treatment Duration (Days)				
n	85	95	72	252
Mean	149.5	86.8	112.2	115.2
Median	182.0	63.0	96.5	132.0
SD	60.35	70.47	65.52	70.71
Min	7	1	15	1
Max	210	212	200	212

-
- 1.) Baseline is defined as the last non-missing value prior to the first dose.
 - 2.) Treatment duration is calculated as: (last dose date - first dose date) + 28 days.
 - 3.) Age is collected in years.